Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationClin Interv Aging. 2008, 3(1):45-50
AbstractRaloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the incidence of vertebral fractures by 30%-50% in postmenopausal women with osteoporosis but has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only medical treatments that are proven to prevent hip fractures with the exception of vitamin D and calcium replacement, which has been shown to prevent hip fractures in elderly individuals and nursing home residents. Raloxifene has been shown to have additive effects on bone turnover and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer. The increased incidence of venous thromboembolism is the main concern of raloxifene therapy and previous history of venous thromboembolism is a contraindication for use of raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The decision to use raloxifene should be based on evaluation of fracture risk and on potential other benefits than fracture reduction along with consideration of side effects.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
- Authors: Cranney A, Adachi JD
- Issue date: 2005
- Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
- Authors: Ko SS, Jordan VC
- Issue date: 2011 Mar
- Raloxifene: a review of its use in postmenopausal osteoporosis.
- Authors: Clemett D, Spencer CM
- Issue date: 2000 Aug
- Raloxifene: recent information on skeletal and non-skeletal effects.
- Authors: Gluck O, Maricic M
- Issue date: 2002 Jul
- A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
- Authors: Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J
- Issue date: 2005 Jun